News | Vascular Closure Devices | December 16, 2015

Manta Vascular Closure Device Safely Closes Large Bore Arterial Access Sites

Device performed closures without complications and exhibited favorable healing characteristics
 

December 16, 2015 — Scientists at CBSET have presented preclinical evidence that the Manta Large Bore Vascular Closure Device (VCD) from Essential Medical successfully closed large bore arterial access without complication. The study, presented at the Innovations in Cardiovascular Medicine (ICI) meeting in Tel Aviv, Israel, also showed the Manta VCD exhibited favorable healing characteristics as assessed by serial histomorphology.

Vascular access site complications are a significant source of morbidity following percutaneous catheterization, especially for interventions requiring large bore cannulation, such as transcatheter aortic valve replacement (TAVR). These complications cause a long time to achieve hemostasis and extend OR time, requiring the need for a vascular surgeon in the cath lab and delaying patient ambulation, causing a high rate of complications and high total cost of care.

“The benefit of a vascular closure device over the standard of manual compression is most pronounced for large bore access and higher baseline-risk patients. The fact that the Manta VCD uses a collagen implant secured by an intraluminal anchor makes it especially suited for large bore cannulation,” said Haim Danenberg, M.D., chief scientific advisor, CBSET, and head of the Cardiovascular Research Center and director of interventional cardiology at the Heart Institute of Hadassah Hebrew University Medical Center, Jerusalem.

“Manta is designed to close a large arteriotomy left by vascular access sheaths in high-pressure vessels in less than 60 seconds, providing immediate hemostasis in order to reduce complications associated with large bore closure,” said study director Lynn Bailey, director of interventional services, CBSET.

“In our study, the MANTA VCD rapidly achieved patent hemostasis, and there was no evidence of vascular occlusion or other complications on long-term follow-up,” added lead author Kenta Nakamura, M.D., fellow in cardiovascular disease at Massachusetts General Hospital; and, research fellow in applied sciences, CBSET. “The device was well-tolerated with favorable cellular response and tissue healing on histopathology.”

In July 2015, Essential Medical announced that it had successfully commenced EU clinical studies using its Manta Large Bore VCD, designed to seal both 14F and 18F large bore femoral punctures. Cases were conducted by Nicholas Van Mieghem, M.D., Ph.D., medical director of the Department of Interventional Cardiology at the Thoraxcenter, Erasmus Medical Center, who commented that MANTA, "is a revolutionary device that will transform how we close cases."

For more information: www.cbset.org

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init